Effect of intravenous administration of paracetamol on morphine consumption in cancer pain control

Tasmacioglu, Buket; Aydınlı, Işık; Keskinbora, Kader; Pekel, Ali Ferit; Salihoğlu, Tamer; Sonsuz, Abdullah

doi:10.1007/s00520-009-0612-8

Cited by 23 publications

(29 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The 2004 cutoff was used because the meta‐analyses included studies that were published up until 2004. Six studies in adults with chronic cancer pain, pain from propofol injection, and migraine were also discussed …”

Section: Clinical Trialsmentioning

confidence: 99%

“…Six randomized studies examined the use of intravenous acetaminophen in patients experiencing nonsurgical pain; two studies each evaluated pain associated with a propofol injection and renal colic, and one study each assessed chronic cancer pain and migraines . Both studies in patients receiving propofol injections showed that low‐dose intravenous acetaminophen (0.5–2 mg/kg or 50 mg) was significantly more effective in relieving pain compared with placebo .…”

Section: Clinical Trialsmentioning

confidence: 99%

“…Six studies in adults with chronic cancer pain, pain from propofol injection, and migraine were also discussed. [41][42][43][44][45][46] Abdominal Surgery Seven randomized controlled trials (including one pivotal trial in the United States) 4,5,15,[19][20][21][22] and one observational comparative study 23 were identified. The pivotal study in the United States showed that intravenous acetaminophen significantly reduced pain but not morphine consumption or adverse events in patients who were undergoing abdominal laparoscopic surgery.…”

Section: Studies In Adult Painmentioning

confidence: 99%

See 2 more Smart Citations

Clinical and Economic Evidence for Intravenous Acetaminophen

Yeh

Reddy

2012

Pharmacotherapy

View full text Add to dashboard Cite

Intravenous acetaminophen received United States Food and Drug Administration approval in November 2010 for the management of mild-to-moderate pain, management of moderate-to-severe pain with adjunctive opioid analgesics, and reduction of fever. Although intravenous acetaminophen generally improved pain relief and demonstrated opioid-sparing effects compared with placebo, it did not consistently reduce the frequency of opioid-related adverse events (e.g., postoperative nausea and vomiting). The safety and efficacy of intravenous acetaminophen as an antipyretic agent have been documented in adults and children; however, its cost is several-fold higher than that of the oral and rectal formulations. Although use of intravenous acetaminophen has reduced other postoperative resource utilization (e.g., hospital length of stay) in some studies outside the United States in patients undergoing abdominal surgery, a full economic evaluation in the United States has yet to be undertaken. In addition, its administration time (15-min infusion) and packaging (glass, single-use vial) have the potential to adversely affect patient flow in the postanesthesia care unit, create burden on patient care units, and lead to drug waste. Furthermore, 1 g of intravenous acetaminophen is formulated in 100 ml of solution, which may be an issue for patients with fluid restrictions. Given the clinical and economic evidence currently available, intravenous acetaminophen should not replace oral or rectal acetaminophen, but its use may be considered in a limited number of patients who cannot receive drugs orally and rectally and who cannot tolerate other parenteral nonopioid analgesic or antipyretic agents.

show abstract

Section: Clinical Trialsmentioning

confidence: 99%

Section: Clinical Trialsmentioning

confidence: 99%

Section: Studies In Adult Painmentioning

confidence: 99%

See 1 more Smart Citation

Clinical and Economic Evidence for Intravenous Acetaminophen

Yeh

Reddy

2012

Pharmacotherapy

View full text Add to dashboard Cite

show abstract

“…[100–3106–11118–20122129139144145153158164176180] Among the original articles, there were 12 qualitative studies[115116118–20122124126–8155169–71173] and 56 quantitative studies. [89–99104105112–4117121123125130–8140–3146–52154156157159–63165–8172174175177–9] There were eight randomized clinical trials,[94143150157161162167177] 12 non-randomized clinical trials,[8999113125137147149151163172175178] 11 cohort studies,[9597121123130131133154156165168] zero case-control studies, 10 cross-sectional studies[9396114…”

Section: Resultsmentioning

confidence: 99%

“…The six systematic reviews[129153158164176180] and eight randomized clinical trials[94143150157161162167177] provided an evidence base as found from this review. The systematic reviews constituted 6.52% (6/92) and randomized clinical trials 8.69% (8/92) of the 92 cancer pain articles.…”

Section: Resultsmentioning

confidence: 99%

Reporting characteristics of cancer pain: A systematic review and quantitative analysis of research publications in palliative care journals

Kumar

2011

Indian J Palliat Care

View full text Add to dashboard Cite

Objective:A common disorder requiring symptom palliation in palliative and end-of-life care is cancer. Cancer pain is recognized as a global health burden. This paper sought to systematically examine the extent to which there is an adequate scientific research base on cancer pain and its reporting characteristics in the palliative care journal literature.Materials and Methods:Search conducted in MEDLINE and CINAHL sought to locate all studies published in 19 palliative/ hospice/ supportive/ end-of-life care journals from 2009 to 2010. The journals included were: American Journal of Hospice and Palliative Care, BMC Palliative Care, Current Opinion in Supportive and Palliative Care, End of Life Care Journal, European Journal of Palliative Care, Hospice Management Advisor, Indian Journal of Palliative Care, International Journal of Palliative Nursing, Internet Journal of Pain Symptom Control and Palliative Care, Journal of Pain and Palliative Care Pharmacotherapy, Journal of Palliative Care, Journal of Palliative Medicine, Journal of Social Work in End-of-life and Palliative Care, Journal of Supportive Oncology, Palliative Medicine, Palliative and Supportive Care, and Supportive Care in Cancer. Journal contents were searched to identify studies that included cancer pain in abstract.Results:During the years 2009 and 2010, of the selected 1,569 articles published in the journals reviewed, only 5.86% (92 articles) were on cancer pain.Conclusion:While researchers in the field of palliative care have studied cancer pain, the total percentage for studies is still a low 5.86%. To move the field of palliative care forward so that appropriate guidelines for cancer pain management can be developed, it is critical that more research be reported upon which to base cancer pain therapy in an evidence-based palliative care model.

show abstract

Systematic review and meta‐analysis on non‐opioid analgesics in palliative medicine

Schüchen

Mücke

Marinova

et al. 2018

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

Non‐opioid analgesics are widely used for pain relief in palliative medicine. However, there is a lack of evidence‐based recommendations addressing the efficacy, tolerability, and safety of non‐opioids in this field. A comprehensive systematic review and meta‐analysis on current evidence can provide a basis for sound recommendations in clinical practice. A database search for controlled trials on the use of non‐opioids in adult palliative patients was performed in Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, PsycINFO, and EMBASE from inception to 18 February 2018. Endpoints were pain intensity, opioid‐sparing effects, safety, and quality of life. Studies with similar patients, interventions, and outcomes were included in the meta‐analyses. Our systematic search was able to only identify studies dealing with cancer pain. Of 5991 retrieved studies, 43 could be included (n = 2925 patients). There was no convincing evidence for satisfactory pain relief by acetaminophen alone or in combination with strong opioids. We found substantial evidence of moderate quality for a satisfactory pain relief in cancer by non‐steroidal anti‐inflammatory drugs (NSAIDs), flupirtine, and dipyrone compared with placebo or other analgesics. There was no evidence for a superiority of one specific non‐opioid. There was moderate quality of evidence for a similar pain reduction by NSAIDs in the usual dosage range compared with up to 15 mg of morphine or opioids of equianalgesic potency. The combination of NSAID and step III opioids showed a beneficial effect, without a decreased tolerability. There is scarce evidence concerning the combination of NSAIDs with weak opioids. There are no randomized‐controlled studies on the use of non‐opioids in a wide range of end‐stage diseases except for cancer. Non‐steroidal anti‐inflammatory drugs, flupirtine, and dipyrone can be recommended for the treatment of cancer pain either alone or in combination with strong opioids. The use of acetaminophen in the palliative setting cannot be recommended. Studies are not available for long‐term use. There is a lack of evidence regarding pain treatment by non‐opioids in specific cancer entities.

show abstract

Effect of intravenous administration of paracetamol on morphine consumption in cancer pain control

Cited by 23 publications

References 19 publications

Clinical and Economic Evidence for Intravenous Acetaminophen

Clinical and Economic Evidence for Intravenous Acetaminophen

Reporting characteristics of cancer pain: A systematic review and quantitative analysis of research publications in palliative care journals

Systematic review and meta‐analysis on non‐opioid analgesics in palliative medicine

Contact Info

Product

Resources

About